The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.
 
Nicholas I. Simon
No Relationships to Disclose
 
Scot Anthony Niglio
Employment - STEMCELL Technologies (I)
Other Relationship - STEMCELL Technologies (I)
 
Elias Chandran
Stock and Other Ownership Interests - Pacific Edge Biotechnology
 
Giovanni Maria Iannantuono
No Relationships to Disclose
 
Salah Boudjadi
No Relationships to Disclose
 
Rouf Banday
No Relationships to Disclose
 
Daniel da Motta Girardi
Consulting or Advisory Role - BMS Brazil; Janssen Oncology
Speakers' Bureau - Bayer; BMS Brazil; Ipsen; Janssen; Merck; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Lisa M. Cordes
No Relationships to Disclose
 
Lisa Ley
No Relationships to Disclose
 
Sandeep Gurram
No Relationships to Disclose
 
Andre Rashad Kydd
No Relationships to Disclose
 
Jennifer C Jones
Patents, Royalties, Other Intellectual Property - NCI IP relating to liquid biopsies, including EV and viral detection and analysis. Stanford University IP relating to TIM family proteins.
 
Kilian Elizabeth Salerno
No Relationships to Disclose
 
Krishnan Patel
No Relationships to Disclose
 
Vladimir Valera
No Relationships to Disclose
 
Howard L. Parnes
Stock and Other Ownership Interests - Gilead Sciences; Health Care Select Sector; Illumina; Intellia Therapeutics; Intuitive Surgical; IQVIA; Roche; Roper Technologies; Schlumberger
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); Propella Therapeutics (Inst); TRACON Pharma (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Jeffrey Schlom
Research Funding - Bavarian Nordic (Inst); EMD Serono/Merck (Inst); ImmunityBio (Inst); Incyte (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - If applicable; If applicable (Inst)
 
Andrea B. Apolo
No Relationships to Disclose